Cancer immunotherapy company CEL-SCI Corporation (NYSE American:CVM) said on Tuesday that the underwriters have announced the full exercise of 90,959 additional shares of common stock in over-allotment option in connection with its underwritten public offering.

The company had issued 606,395m shares of its common stock under its prior underwritten public offering.

Following the full exercise of the underwriters' over-allotment option, the company raised total gross proceeds from the offering of USD6.325m.

Aegis Capital Corp acted as the sole book-running manager for the offering.

CEL-SCI's lead investigational therapy Multikine is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the company has received Orphan Drug Status from the FDA.